Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

NVIDIA's Head of Healthcare & Life Sciences EMEA looks ahead to the three ways AI will support healthcare in 2025.

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

Siddhartha Mukherjee and Reid Hoffman’s Manas AI aims to help design and screen molecules that ... we can now help the world's best drug development scientists to augment and amplify their ...

Acellera Therapeutics focuses on drug discovery by merging AI-driven innovation with computational scaleability, aiming to ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

AI, and cloud computing towards improving existing computational methods while exploring new algorithms to address a wide range of drug design challenges. “We look forward to helping expedite ...

List of Molecular and Material design using Generative AI and Deep Learning ...

an AI model trained on billions of natural protein sequences, to design a functional protein beyond evolutionary constraints. The development is expected to accelerate medical research, drug ...

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure ...